Skyepharma PLC: SkyePharma PLC announces Succession Plan
                   
marketwire.com     21-May-2008            

London, UK--(Marketwire - At its Annual General Meeting later today, SkyePharma PLC will announce that its Chief Executive Officer, Frank Condella, intends to step down from his executive position once the Company has completed its financial restructuring by refinancing or renegotiating its... [read full story]                    


View all news articles about*:
ALZA Corporate Corporation David England General GlaxoSmithKline Greater Issues Japan Kingdom Kos London Management Marketwire Pharmaceuticals Restructuring SkyePharma United Yates
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

Portola Packaging, Inc. Receives First Day Orders Allowing Continuation of Business in Ordinary Co..

euroinvestor.co.uk     12 hrs ago   2 related          

course. It has received court orders authorizing the Company to pay prepetition claims of unsecured creditors in the ordinary course of business. In addition, the Company received authorization to utilize the existing...                    

comments

Amy Wino's dad aims for Spurs

thesun.co.uk     1 hr ago          

AMY WINEHOUSE’s dad MITCH is close to clinching his Hart’s desire — to sit on the board of directors at Tottenham Hotspur FC. The cabbie, a life-long Spurs fan, is putting all of his spare cash into buying shares in the...                    

comments

                   

SykePharma shares surge on hopes for bonds deal

pharmiweb.co.uk     yesterday          

LONDON (Reuters) - Britain's SkyePharma Plc, a specialist in drug delivery technology, said on Thursday it was close to a deal on renegotiating its convertible bonds, sending the company's shares 20 percent higher. The...                    

comments

                   

SkyePharma: Interim Results Announcement for the Six Months Ended 30 June 2008

pharmiweb.co.uk     yesterday   5 related          

shortly. Jeremy Scudamore, Non-Executive Chairman, said: “In the last six months SkyePharma has made significant progress on several fronts. Positive Flutiform™ data has now been received from seven Phase III clinical...                    

comments